My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by NewAmsterdam Pharma N.V.

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.